Background Antimicrobial resistance (AMR) is a global problem. Resistant bacteria, for
many reasons, do not cease to emerge and re-emerge. The impact of AMR on patient …

Background: In decentralized sites, with fewer resources and a high prevalence of advanced
HIV, the effectiveness of the new short-course, bedaquiline-based regimen for rifampicin …

SETTING: According to reports in South Africa, treatment failure rates for rifampicin-resistant
TB (RR-TB) are significant and below the WHO target of≥ 70%. HIV infection and the use of …

Abstract Background The emergence of Drug Resistant Tuberculosis (DR-TB) is one of the
main public health and economic problems facing the world today. DR-TB affects mostly …

Objective: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis,
which causes disease in all organs, 80% of which are in the lungs, and can sometimes …

Background: Three phase II clinical trials generated the evidence for recommending
bedaquiline for the treatment of rifampicin-resistant tuberculosis (RR-TB). These trials were …

Abstract A series of novel 3, 4, 7-or 3, 4, 8-trisubstituted-3a, 4-dihydro [1, 2, 3] triazolo [1, 5-a]
quinazolin-5 (3 H)-one analogues was synthesized and characterized by using HRMS, 1H …

M. tuberculosis до амікацину та канаміцину. Рівень резистентності досліджуваних
ізолятів до капреоміцину та моксифлоксацину був вищим щодо їх стійкості до …

Drug-resistant tuberculosis (DR TB) is a disease that impacts public health with its
increasing number of cases. Using data from the national cross-sectional Anti-Tuberculosis …